Alterity Therapeutics (ATHE) News Today → Wall Street legend who predicted 2021 tech crash issues new warning (From Chaikin Analytics) (Ad) Free ATHE Stock Alerts $2.04 -0.06 (-2.86%) (As of 05/15/2024 ET) Add Compare Share Share HeadlinesStock AnalysisAnalyst ForecastsChartCompetitorsFinancialsHeadlinesSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsFinancialsHeadlinesSEC FilingsShort InterestSocial Media All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative May 8, 2024 | globenewswire.comAlterity Therapeutics Phase 2 Data Monitoring Committee Recommends Continuing Clinical Trial as Planned After Third ReviewApril 30, 2024 | globenewswire.comAppendix 4C – Q3 FY24 Quarterly Cash Flow ReportApril 29, 2024 | finance.yahoo.comAlterity Therapeutics Presents New Data Demonstrating Potential of ATH434 to Treat Rare Neurodegenerative Disease Friedreich’s AtaxiaApril 29, 2024 | globenewswire.comAlterity Therapeutics Presents New Data Demonstrating Potential of ATH434 to Treat Rare Neurodegenerative Disease Friedreich's AtaxiaApril 17, 2024 | finance.yahoo.comAlterity Therapeutics Parkinson’s Disease and Multiple System Atrophy Data Featured at the American Academy of Neurology (AAN) 2024 Annual MeetingApril 10, 2024 | globenewswire.comAlterity Therapeutics to Present New Data on ATH434 at the World Orphan Drug Congress USA 2024April 5, 2024 | finance.yahoo.comAlterity Therapeutics Limited (ATHE)March 26, 2024 | globenewswire.comAlterity Therapeutics Receives a A$3.9 Million Research & Development Tax Incentive RefundMarch 24, 2024 | morningstar.comAlterity Therapeutics Ltd ADR ATHEMarch 22, 2024 | seekingalpha.comATHE Alterity Therapeutics LimitedMarch 22, 2024 | wsj.comAlterity Therapeutics Ltd. ADRFebruary 23, 2024 | msn.comAlterity Therapeutics drops on capital raiseFebruary 22, 2024 | benzinga.comAlterity Therapeutics Stock (NASDAQ:ATHE), Short Interest ReportFebruary 21, 2024 | marketbeat.comTrading was temporarily halted for "ATHE" at 05:02 PM with a stated reason of "News pending."February 20, 2024 | finance.yahoo.comAlterity Therapeutics to Present New Data at the Upcoming American Academy of Neurology 2024 Annual MeetingFebruary 20, 2024 | globenewswire.comAlterity Therapeutics to Present New Data at the Upcoming American Academy of Neurology 2024 Annual MeetingJanuary 29, 2024 | finance.yahoo.comAlterity Therapeutics to Participate in the ShareCafe Hidden Gems Webinar This WeekJanuary 22, 2024 | finance.yahoo.comAlterity Therapeutics Issues Shareholder Letter Highlighting Pipeline Advances and Key Upcoming MilestonesDecember 21, 2023 | finanznachrichten.deALTERITY THERAPEUTICS LIMITED: Alterity Therapeutics Appoints Phillip Hains as Chief Financial OfficerDecember 4, 2023 | finance.yahoo.comAlterity Therapeutics to Host Webcast to Discuss ATH434 Efficacy Data in Primates and Recent Clinical ProgressDecember 4, 2023 | marketwatch.comAlterity Therapeutics Shares Up Fivefold on New Parkinson's Drug DataDecember 4, 2023 | msn.comWhy Is Neurodegenerative Disease-Focused Alterity Therapeutics Stock Trading Over 200% Higher Today?December 4, 2023 | finance.yahoo.comBiotech Alterity Jumps On Upbeat Parkinson's Treatment Clinical Trial DataDecember 4, 2023 | finance.yahoo.comAlterity Therapeutics Reports Positive Efficacy Data for ATH434 in a Primate Model of Parkinson’s DiseaseNovember 27, 2023 | finance.yahoo.comAlterity Therapeutics Announces Presentation of Novel Biomarker Data for Evaluation of Multiple System AtrophyNovember 22, 2023 | finance.yahoo.comAlterity Therapeutics Limited's (ASX:ATH) CEO Compensation Is Looking A Bit Stretched At The MomentNovember 22, 2023 | msn.comAlterity Therapeutics, Edesa Biotech among healthcare moversNovember 22, 2023 | marketwatch.comAlterity Therapeutics ADRs Shares Dive 31% on Raised CapitalNovember 20, 2023 | marketbeat.comTrading was temporarily halted for "ATHE" at 06:11 AM with a stated reason of "News pending."November 16, 2023 | finanznachrichten.deALTERITY THERAPEUTICS LIMITED: Alterity Therapeutics Announces Presentation of New Data Demonstrating Novel Mechanisms of ATH434November 16, 2023 | finance.yahoo.comAlterity Therapeutics Announces Presentation of New Data Demonstrating Novel Mechanisms of ATH434November 8, 2023 | finanznachrichten.deALTERITY THERAPEUTICS LIMITED: Alterity Therapeutics Completes Enrolment in ATH434-201 Phase 2 Clinical Trial in Multiple System AtrophyOctober 30, 2023 | finance.yahoo.comAppendix 4C – Q1 FY24 Quarterly Cash Flow ReportAugust 31, 2023 | finance.yahoo.comAlterity Therapeutics Presents New Data on Multiple System Atrophy, a Rare Parkinsonian DisorderAugust 23, 2023 | finance.yahoo.comAlterity Therapeutics Granted New Composition of Matter Patent in Europe for Neurodegenerative Diseases including Parkinson’s and Alzheimer’sAugust 22, 2023 | technews.tmcnet.comAlterity Therapeutics Rare Disease Natural History Study to be Featured at the International Congress of Parkinson's Disease and Movement DisordersAugust 22, 2023 | finance.yahoo.comAlterity Therapeutics Rare Disease Natural History Study to be Featured at the International Congress of Parkinson’s Disease and Movement DisordersAugust 15, 2023 | finance.yahoo.comAlterity Therapeutics Receives a $4.74 million Research & Development Tax Incentive RefundJuly 31, 2023 | finance.yahoo.comAppendix 4C – Q4 FY23 Quarterly Cash Flow ReportJuly 26, 2023 | finance.yahoo.comAlterity Therapeutics Phase 2 Data Monitoring Committee Recommends Continuing Clinical Trial as PlannedJune 21, 2023 | finance.yahoo.comAlterity Therapeutics to Present in MST Access Rare Diseases, Rich Returns Forum on 22 June 2023May 30, 2023 | finance.yahoo.comAlterity Therapeutics Initiates Second Phase 2 Study in Rare Parkinsonian DisorderMay 19, 2023 | finance.yahoo.comAlterity Therapeutics CEO David Stamler to Present at the SHARE Series Monday Management Update on Monday, May 22, 2023May 10, 2023 | finance.yahoo.comAppendix 4C – Q3 FY23 Quarterly Cash Flow ReportMay 10, 2023 | finance.yahoo.comAlterity Therapeutics Enrolls First Patient in Australia in ATH434 Global Phase 2 Clinical Trial in Multiple System AtrophyApril 26, 2023 | finance.yahoo.comAlterity Therapeutics Presents Promising Wearable Sensor Data from the bioMUSE Natural History Study at the American Academy of NeurologyMarch 14, 2023 | msn.comAlterity gets US patent, inks licensing pact to advance asset for Alzheimer'sMarch 14, 2023 | finance.yahoo.comAlterity Therapeutics Announces Granting of New Composition of Matter Patent and Exclusive License Agreement for Assets in Alzheimer’s DiseaseMarch 8, 2023 | finance.yahoo.comAlterity Therapeutics Enrolls First Patient in Italy in ATH434 Phase 2 Clinical Trial in Multiple System AtrophyJanuary 31, 2023 | finance.yahoo.comAppendix 4C - Q2 FY23 Quarterly Cash Flow Report Get Alterity Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for ATHE and its competitors with MarketBeat's FREE daily newsletter. Email Address A ‘DeFi Summer’ Projected! (Ad)Top analysts are predicting DeFi coins to see massive gains in the coming months… During this dubbed ‘DeFi Summer…’ A coin that has been called the “DeFi pioneer” is poised to shoot up 3-7x! Just click here to learn how you can access this coin right now. ATHE Media Mentions By Week ATHE Media SentimentLearn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. ATHE News Sentiment▼1.250.55▲Average Medical News Sentiment ATHE News CoverageLearn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. ATHE Articles This Week▼20▲ATHE Articles Average Week Get Alterity Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for ATHE and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies: CMMB News Today AEZS News Today ADXN News Today GRTX News Today GHSI News Today MTEM News Today ERNA News Today ABVC News Today MIRA News Today MBRX News Today Headlines Tools: Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:ATHE) was last updated on 5/16/2024 by MarketBeat.com Staff From Our PartnersBiden to Drop BOMBSHELL June 13th?Paradigm PressAmazon's betting big on this unknown AI companyManward PressThis Wall Street stock prediction just went viralChaikin AnalyticsThe #1 Biotech Stock to Watch in 2024 is Attacking Viruses in a Unique WaySmallcaps DailyTrump’s “Tax Free” Retirement Strategy Gold Safe ExchangeHealthcare Takes A Big Step Forward With The Help Of AIThe Bull ReportTop 5 AI Stocks to Buy for 2024Market Moving TrendsTop 5 Tech Stocks to Buy for 2024Daily Market Alerts Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Alterity Therapeutics Limited Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
